Patent ID: 6906063

Claim:
A compound of the following formula: wherein: A is thienyl, optionally substituted with from one to two halogen atoms; W is phenylene, optionally substituted with from one to two substituents selected from the group consisting of halogen, methyl and trifluoromethyl; E is selected from the group consisting of H, —C 1 -C 8 alkyl, polyhaloalkyl and —C 3-8 -cycloalkyl; n is an integer from 0-4; each instance of X 1 , X 2 and X 3 is a member independently selected from the group consisting of hydrogen, halogen, polyhaloalkyl, —OR 3 , —SR 3 , —CN, —NO 2 , —SO 2 R 3 , —CONHR 3 , —C(═NH)NHCH 3 , —C 1-10 -alkyl, —C 3-8 -cycloalkyl, aryl, aryl-substituted by 1-4 R 3 groups, amino, amino-C 1-8 -alkyl, C 1-3 -acylamino, C 1-3 -acylamino-C 1-8 -alkyl, C 1-6 -alkylamino, C 1-6 -alkylamino C 1-8 -alkyl, C 1-6 dialkylamino, C 1-6 dialkylamino C 1-8 -alkyl, C 1-6 -alkoxy, C 1-6 -alkoxy-C 1-6 -alkyl, carboxy-C 1-6 -alkyl, C 1-3 -alkoxycarbonyl, C 1-3 -alkoxycarbonyl-C 1-6 -alkyl, carboxy C 1-6 alkyloxy, hydroxy, hydroxy C 1-6 alkyl, a 5 membered fused pyrrolidino, imidazolo, thiazolo or oxazolo ring and a 5 to 6 membered aromatic or nonaromatic heterocyclic ring selected from the group consisting of oxazolinyl, pyrrolidinyl, imidazolinyl and pyridyl, with proviso that the carbon and nitrogen atoms, when present in the heterocyclic ring, are unsubstituted, mono- or di-substituted independently with 0-2 R 4 groups; R 3 and R 4 are each independently selected from the group consisting of hydrogen, halogen, —CN, —NO 2 , —C 1-10 alkyl, C 3-8 -cycloalkyl, aryl, amino, amino-C 1-8 -alkyl, C 1-3 -acylamino, C 1-3 -acylamino-C 1-8 -alkyl, C 1-6 -alkylamino, C 1-6 -alkylamino C 1-8 alkyl, C 1-6 dialkylamino C 1-6 dialkylamino C 1-8 alkyl, C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 -alkyl, carboxy-C 1-6 -alkyl, C 1-3 -alkoxycarbonyl, C 1-3 -alkoxycarbonyl-C 1-6 alkyl, carboxy-C 1-6 -alkyloxy, hydroxy, hydroxy-C 1-6 -alkyl, -thio and thio-C 1-6 -alkyl, wherein optionally two alkyl groups attached to a nitrogen atom can be combined with the nitrogen atom to form a pyrrolidinyl, piperidinyl or morpholinyl ring; Y is selected from the group consisting of O, S, N—OR 5 and NR 5 ; R 5 is selected from the group consisting of H, C 1-10 alkyl, C 3-8 -cycloalkyl, and CN; or pharmaceutically acceptable salts.